

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

Date of mailing (day/month/year) 04 July 2001 (04.07.01)	
International application No. PCT/US00/21173	Applicant's or agent's file reference 03063-0551WP
International filing date (day/month/year) 03 August 2000 (03.08.00)	Priority date (day/month/year) 05 August 1999 (05.08.99)
Applicant TSANG, Victor, C., W. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
23 February 2001 (23.02.01)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer H. Zhou Telephone No.: (41-22) 338.83.38
---	---

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

NOONAN, William, D.M.D.  
KLARQUIST, SPARKMAN, CAMPBELL,  
LEIGH & WHINSTON, L.L.P.  
One World Trade Center  
121 S.W. Salmon Street, Suite 1600  
Portland, Oregon 97204-2988  
ETATS-UNIS D'AMERIQUE

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year) 25.10.2001

Applicant's or agent's file reference  
6395-56702

**IMPORTANT NOTIFICATION**

International application No.  
PCT/US00/21173

International filing date (day/month/year)  
03/08/2000

Priority date (day/month/year)  
05/08/1999

Applicant  
THE GOVERNMENT OF THE UNITED STATES OF AMERICA ...

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

**4. REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office - P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk - Pays Bas  
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl  
Fax: +31 70 340 - 3016

Authorized officer

Cardenas, C

Tel. +31 70 340-3370



# ENT COOPERATION TREATY

## PCT

### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>03063-0551WP</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 00/ 21173</b>	International filing date (day/month/year) <b>03/08/2000</b>	(Earliest) Priority Date (day/month/year) <b>05/08/1999</b>
Applicant  <b>THE GOVERNMENT OF THE UNITED STATES OF AMERICA ...</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.  
☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☐ None of the figures.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/21173

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12N15/12 C07K14/435 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K C12N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, EMBL, BIOSIS, CHEM ABS Data, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RYAN M. GREENE ET AL.: "Diagnostic glycoproteins of Taenia solium cysts share homologous 14- and 18kDa subunits" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 99, no. 2, 30 April 1999 (1999-04-30), pages 257-261, XP000979008</p> <p>page 258, right-hand column, paragraph 3 -page 260, left-hand column, paragraph 3 &amp; DATABASE EMBL 'Online! Entry AF082830, 1 September 1999 (1999-09-01)</p> <p>GREENE R.M. ET AL.: "Taenia solium RS1 mRNA" &amp; DATABASE EMBL 'Online! Entry AF082828, 1 September 1999 (1999-09-01)</p> <p>GREENE R.M. ET AL.: "Taenia solium 18kDa glycoprotein TS18 precursor"</p> <p style="text-align: right;">-/--</p>	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

23 January 2001

Date of mailing of the international search report

06/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>-----</p> <p>US 5 354 660 A (VICTOR C.W. TSANG ET AL.)  11 October 1994 (1994-10-11)  cited in the application  column 2, line 4 - line 39  column 3, line 4 - line 37; examples 1-3</p>	1,2,8,9, 13
X	<p>-----</p> <p>CHARLES G.P. GAUCI ET AL.: "A Taenia solium oncosphere protein homologous to host-protective Taenia ovis and Taenia saginata 18 kDa antigens"  INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 28, May 1998 (1998-05), pages 757-760, XP000978965  page 757, right-hand column, paragraph 2  -page 759, right-hand column, paragraph 1; figures 1,2</p>	1,2,8,9, 13
X	<p>-----</p> <p>HUBERT K ET AL: "SEROLOGICAL DIAGNOSIS OF HUMAN CYSTICERCOSIS BY USE OF RECOMBINANT ANTIGENS FROM TAENIA SOLIUM CYSTICERCI" CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 6, no. 4, July 1999 (1999-07), pages 479-482, XP000965375  ISSN: 1071-412X  abstract  page 479, right-hand column, last paragraph -page 480, left-hand column, paragraph 3  page 480, left-hand column, last paragraph -page 481, right-hand column, paragraph 2</p>	1,8,13
X	<p>-----</p> <p>US 4 801 532 A (RAYMOND E. KUHN ET AL.)  31 January 1989 (1989-01-31)  column 4, line 8 -column 7, line 33;  examples</p>	1,8,13
X	<p>-----</p> <p>C. SIMAC ET AL.: "Use of enzyme-linked immunosorbent assay and enzyme-linked immunoelectrotransfer blot for the diagnosis and monitoring of neurocysticercosis"  PARASITOLOGY RESEARCH, vol. 81, 1995, pages 132-136, XP000978991  page 133, right-hand column, paragraph 4  -page 135, right-hand column, paragraph 2</p> <p>-----</p> <p>-/--</p>	1,2,8,9, 13

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/21173

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GREENE RM ET AL.: "Molecular cloning and serological evaluation of taenia solium diagnostic" AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 61, September 1999 (1999-09), page 178 XP000978963 abstract no. 65 ---	1-16
P,X	DATABASE EMBL 'Online! Entry AF257776, 3 May 2000 (2000-05-03) TEALE J.M. ET AL.: "Taenia solium 14kDa glycoprotein mRNA" Database accession no. AF257776 XP002158230 the whole document -----	1-16

# INTERNATIONAL SEARCH REPORT

International Application No

on patent family members

PCT/US 00/21173

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5354660	A	11-10-1994	NONE	
US 4801532	A	31-01-1989	US 4740456 A US 4855408 A	26-04-1988 08-08-1989

INTERNATIONAL COOPERATION TREATY

DEPOSIT  
DEPOSITOR

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

KS

To:  
Kilpatricks Stockton, LLP  
2400 Monarch Tower  
Attn. GREENE, Jamie L.  
3424 Peachtree Road, N.E.  
Atlanta, GA 30326  
UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
FOR THE DECLARATION

FEB 13 2001

(PCT Rule 44.1)

Date of mailing (day/month/year)	06/02/2001
Applicant's or agent's file reference 03063-0551WP	<b>FOR FURTHER ACTION</b> See paragraphs 1 and 4 below
International application No. PCT/US 00/21173	International filing date (day/month/year) 03/08/2000
Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA ...	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

**For more detailed instructions,** see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Catherine Humbert

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.



For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

# PCT

REC'D 24 OCT 2001

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>6395-56702</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) <b>FOR FURTHER ACTION</b>	
International application No. <b>PCT/US00/21173</b>	International filing date (day/month/year) <b>03/08/2000</b>	Priority date (day/month/year) <b>05/08/1999</b>	
International Patent Classification (IPC) or national classification and IPC <b>C07K14/00</b>			
Applicant <b>THE GOVERNMENT OF THE UNITED STATES OF AMERICA ...</b>			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input checked="" type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand <b>23/02/2001</b>		Date of completion of this report <b>25.10.2001</b>	
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016		Authorized officer  <b>Montero Lopez, B</b>  Telephone No. +31 70 340 3739 	

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/21173

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1-26 as originally filed

### Claims, No.:

1-16 as originally filed

### Sequence listing part of the description, pages:

1-5, filed with the letter of 25/10/2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/21173

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	3, 5-7, 10, 12, 14, 16
	No:	Claims	1, 2, 4, 8, 9, 11, 13, 15
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-16
Industrial applicability (IA)	Yes:	Claims	1-16
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: "Molecular and Biochemical Parasitology", 30th April 1999, vol. 99, pages 257-261

1. The underlying application relates to Taenia ovis 14-, 18- and 21-kDa antigenic polypeptides and diagnostic use thereof.

1.1. Document D1, which is considered to represent the most relevant state of the art, discloses (cf. page 258, col. left, par. 3 - page 260, col. left, par. 3) purified antigenic Taenia ovis proteins of 14-, 18- and 21-kDa comprising the sequence IAQLAK (see table I) and their use in the diagnostic of cysticercosis. Consequently, claims 1, 2, 4, 8, 9, 11, 13 and 15 are not novel and do not comply with the requirements of Article 33(2) PCT.

1.2. Claims 3, 5-7, 10, 12, 14 and 16 refer to the sequence of the proteins and of their encoding nucleic acid molecule and comply with the requirements of Article 33(2) PCT.

1.3. In the light of the state of the art the problem underlying the present application consists in the provision of the whole amino acid and nucleotide sequence of, respectively, the 14-, 18, and 21kDa proteins as well as their encoding nucleic acid. The sequencing of isolated proteins and the determination of their corresponding nucleic acid sequence is however a matter of routine in the art which the skilled person would put into practice without the need of exercising any inventive skill. It is considered therefore that claims 3, 5-7, 10, 12, 14 and 16 do not involve an inventive step and do not meet the requirements of Article 33(3) PCT.

**Re Item VII**

**Certain defects in the international application**

1. The vague and imprecise statements in the description on page 25, last paragraph and page 26, lines 30-36 imply that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, III-4.3a).
2. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

**Re Item VIII**

**Certain observations on the international application**

1. It is clear that the features concerning, respectively, the amino acid and nucleic acid sequences SEQ ID NO:1-6 are essential to the definition of the invention. Since independent claims 1, 2, 8, 9 and 13 do not contain these features they do not meet the requirement following from Article 6 PCT taken in combination with Rule 6.3(b) PCT that any independent claim must contain all the technical features essential to the definition of the invention.
2. Claims 1, 8 and 13, by means of the expressions "synthetic or recombinant" and "larval", attempt to define a product, a polypeptide, according to the process to obtain it. However, the method of preparation does not impart any limitation to the product. A claim directed to a product according to the process to obtain the same is therefore construed as a claim to the product as such. The product would be better defined in terms of its own structural features, such as its amino acid sequence (Article 6 PCT).
3. Claims 1, 6, and 7 refer to "isolated" polypeptides and nucleic acid molecules. The applicant is kindly reminded that the degree of isolation is not a technical feature of a preparation and the term "isolated" is therefore disregarded (Article 6 PCT).
4. The designation "T. solium" in claim 1 should be replaced by its whole name, i.e.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/21173

"Taenia solium" (Article 6 PCT).

5. Claims 2 and 9 refers to TS-14, TS-18 and TSRS-1 polypeptides. The use of such arbitrary, internal designations does not provide any technical features to the subject-matter and renders the scope of these claims unclear contrary to Article 6 PCT.

6. The term "fragment" used in claims 1, 8 and 13 is vague and unclear, not identifying the identity or length of the fragment, and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claims unclear (Article 6 PCT).

# PATENT COOPERATION TREATY

*Indie*  
*THH*

DOCKETED FOR 7-27-01

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

NOONAN, William, D.M.D.  
KLARQUIST, SPARKMAN, CAMPBELL,  
LEIGH & WHINSTON, L.L.P.  
One World Trade Center  
121 S.W. Salmon Street, Suite 1600  
Portland, Oregon 97204-2988  
ETATS-UNIS D'AMERIQUE

PCT  
BRIEF  
ANN. SVE

WRITTEN OPINION

(PCT Rule 66)

Date of mailing (day/month/year)		27.04.2001
Applicant's or agent's file reference 6395-56702		REPLY DUE within 3 month(s) from the above date of mailing
International application No. PCT/US00/21173	International filing date (day/month/year) 03/08/2000	Priority date (day/month/year) 05/08/1999
International Patent Classification (IPC) or both national classification and IPC C07K14/00		
Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA ...		

- This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
- This opinion contains indications relating to the following items:
  - ☒ Basis of the opinion
  - ☐ Priority
  - ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - ☐ Lack of unity of invention
  - ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - ☐ Certain document cited
  - ☒ Certain defects in the international application
  - ☒ Certain observations on the international application
- The applicant is hereby **invited to reply** to this opinion.
 

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

**If no reply is filed**, the international preliminary examination report will be established on the basis of this opinion.
- The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 05/12/2001.

Name and mailing address of the international preliminary examining authority:  
European Patent Office - P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk - Pays Bas  
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl  
Fax: +31 70 340 - 3016

Authorized officer / Examiner

Montero Lopez, B

Formalities officer (incl. extension of time limits)  
Sinanovic, E  
Telephone No. +31 70 340 2672



**I. Basis of the opinion**

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

**Description, pages:**

1-26 as originally filed

**Claims, No.:**

1-16 as originally filed

**Sequence listing part of the description, pages:**

1-5, filed with the letter of 25/10/2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

## WRITTEN OPINION

International application No. PCT/US00/21173

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

### V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement
- |                               |        |                           |
|-------------------------------|--------|---------------------------|
| Novelty (N)                   | Claims | 1, 2, 4, 8, 9, 11, 13, 15 |
| Inventive step (IS)           | Claims | 1-16                      |
| Industrial applicability (IA) | Claims |                           |

2. Citations and explanations  
**see separate sheet**

### VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: "Molecular and Biochemical Parasitology", 30th April 1999, vol. 99, pages 257-261

1. The underlying application relates to *Taenia ovis* 14-, 18- and 21-kDa antigenic polypeptides and diagnostic use thereof.

1.1. Document D1, which is considered to represent the most relevant state of the art, discloses (cf. page 258, col. left, par. 3 - page 260, col. left, par. 3) purified antigenic *Taenia ovis* proteins of 14-, 18- and 21-kDa comprising the sequence IAQLAK (see table I) and their use in the diagnostic of cysticercosis. Consequently, claims 1, 2, 4, 8, 9, 11, 13 and 15 are not novel and do not comply with the requirements of Article 33(2) PCT.

1.2. Claims 3, 5-7, 10, 12, 14 and 16 refer to the sequence of the proteins and of their encoding nucleic acid molecule. In the light of the state of the art the problem underlying the present application consists in the provision of the whole amino acid and nucleotide sequence of, respectively, the 14-, 18, and 21kDa proteins as well as their encoding nucleic acid. The sequencing of isolated proteins and the determination of their corresponding nucleic acid sequence is however a matter of routine in the art which the skilled person would put into practice without the need of exercising any inventive skill. It is considered therefore that claims 3, 5-7, 10, 12, 14 and 16 do not involve an inventive step and do not meet the requirements of Article 33(3) PCT.

**Re Item VII**

**Certain defects in the international application**

1. The vague and imprecise statements in the description on page 25, last paragraph

and page 26, lines 30-36 imply that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity (Article 6 PCT) when used to interpret them (see also the PCT Guidelines, III-4.3a).

2. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

**Re Item VIII**

**Certain observations on the international application**

1. It is clear that the features concerning, respectively, the amino acid and nucleic acid sequences SEQ ID NO:1-6 are essential to the definition of the invention. Since independent claims 1, 2, 8, 9 and 13 do not contain these features they do not meet the requirement following from Article 6 PCT taken in combination with Rule 6.3(b) PCT that any independent claim must contain all the technical features essential to the definition of the invention.

2. Claims 1, 8 and 13, by means of the expressions "synthetic or recombinant" and "larval", attempt to define a product, a polypeptide, according to the process to obtain it. However, the method of preparation does not impart any limitation to the product. A claim directed to a product according to the process to obtain the same is therefore construed as a claim to the product as such. The product would be better defined in terms of its own structural features, such as its amino acid sequence (Article 6 PCT).

3. Claims 1, 6, and 7 refer to "isolated" polypeptides and nucleic acid molecules. The applicant is kindly reminded that the degree of isolation is not a technical feature of a preparation and the term "isolated" is therefore disregarded (Article 6 PCT).

4. The designation "T. solium" in claim 1 should be replaced by its whole name, i.e. "Taenia solium" (Article 6 PCT).

5. Claims 2 and 9 refers to TS-14, TS-18 and TSRS-1 polypeptides. The use of such arbitrary, internal designations does not provide any technical features to the subject-

**WRITTEN OPINION  
SEPARATE SHEET**

---

International application No. PCT/US00/21173

matter and renders the scope of these claims unclear contrary to Article 6 PCT.

6. The term "fragment" used in claims 1, 8 and 13 is vague and unclear, not identifying the identity or length of the fragment, and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claims unclear (Article 6 PCT).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number  
**WO 01/10897 A2**

- (51) International Patent Classification<sup>7</sup>: C07K 14/00
- (21) International Application Number: PCT/US00/21173
- (22) International Filing Date: 3 August 2000 (03.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/147,318 5 August 1999 (05.08.1999) US
- (71) Applicant (*for all designated States except US*): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA** as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Centers for Disease Control and Prevention, Technology Transfer Office, Executive Park Drive, Building 4, Suite 1103, M/S E-67, Atlanta, GA 30329 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **TSANG, Victor, C., W.** [US/US]; 2595 Oak Crossing Drive, Decatur, GA 30033 (US). **GREENE, Ryan, M.** [US/US]; 1 Sycamore Station, Decatur, GA 30030 (US). **WILKINS, Patricia, P.** [US/US]; 5608 Hidden Harbor Drive, Gainesville, GA 30504 (US). **HANCOCK, Kathy** [US/US]; 1488 N. Amanda Circle, Atlanta, GA 30329 (US).
- (74) Agent: **NOONAN, William, D.**; Klarquist Sparkman Campbell Leigh & Winston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204-2988 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *Without international search report and to be republished upon receipt of that report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS AND COMPOSITIONS FOR DETECTING LARVAL *TAENIA SOLIUM*

(57) Abstract: Compositions and methods for the detection of *Taenia solium* and the diagnosis and treatment of *T. solium* infection are described. The nucleotide and amino acid sequences of the antigenic polypeptides TS-14, TS-18 and TSRS-1 are provided. The compositions contain antigenic polypeptides of larval origin. The polypeptides are useful as research tools for studying *T. solium* and as reagents in assays for the detection of *T. solium* antibodies in a biological sample. The methods are sensitive and specific assays that utilize the antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.

WO 01/10897 A2

5

1

10

## METHODS AND COMPOSITIONS FOR DETECTING LARVAL *TAENIA SOLIUM*

15

This invention was made by the Centers for Disease Control and Prevention, an agency of the United States Government. Therefore, the United States Government has certain rights in this invention.

### FIELD OF THE INVENTION

20

The present invention relates to the fields of molecular biology and immunology and more specifically relates to compositions and methods for diagnosing cysticercosis. In particular, the invention pertains to synthetic or recombinant *Taenia solium* antigens and their use in immunoassays.

### BACKGROUND OF THE INVENTION

25

*Taenia solium* cysticercosis, caused by infection with *T. solium* larval cysts, occurs in both humans and swine, resulting in significant public health and economic hardship. *T. solium*, also referred to as the pork tapeworm, is a helminth that exists in both a mature tapeworm form and a larval form. The lifecycle of *T. solium* begins when swine, the intermediate hosts, ingest tapeworm eggs excreted in the feces of a tapeworm carrier. The larvae hatch from the eggs and invade most tissues of the swine, giving rise to the disease cysticercosis.

30

35

When humans ingest raw or undercooked meat from cysticercotic swine, tapeworms, or taeniasis, develop. Patients with taeniasis may exhibit epigastric discomfort, nausea, irritability, diarrhea and weight loss. In addition, proglottids, or individual segments of the

## 2

tapeworm that are self-contained hermaphroditic reproductive units, may obstruct the appendix, biliary duct, or pancreatic duct.

Humans may also ingest *T. solium* eggs present in contaminated food and water and serve as intermediate hosts. After *T. solium* eggs are ingested, cysticerci may develop in the subcutaneous tissues, muscles, heart, lungs, liver, brain, and eye. Although small numbers of viable cysticerci fail to produce symptoms in the infected host, death of the larvae stimulate a marked inflammatory reaction, fever, muscle pains, and eosinophilia. If the larvae invade the central nervous system, the host may develop meningoencephalitis, epileptic seizures, dementia and other neurologic or psychiatric manifestations, and can result in death from acute intracranial hypertension. The various manifestations of neurologic disfunction caused by *T. solium* infection are collectively termed neurocysticercosis. Although neurocysticercosis can include many neurological symptoms, epilepsy is the most common symptom. In fact, *T. solium* is considered the leading infectious cause of epileptic seizures worldwide. Additionally, *T. solium* neurocysticercosis has a current worldwide toll of 50 million cases with 50,000 deaths each year.

Neurocysticercosis is rarely acquired in the United States; however, the disease is common in Latin America, Asia, Russia and Eastern Europe. In Mexico, the mean rate for cysticercotic pigs in inspected slaughterhouses during 1980-1981 was 1.55%, and in rural areas of Mexico and South America where sewage disposal is limited, the number of cysticercotic pigs can be in excess of 50%. In these and other developing countries, the parasite causes a substantial economic burden to the pork industry. Additionally, due to the increased travel and immigration from highly endemic areas, detection and treatment of *T. solium* related diseases has become a U.S. public health priority.

Diagnosis historically relied on histological identification of the parasite by biopsy or autopsy. The recent development of radiologic and serologic methods has improved diagnosis. However, while radiologic methods such as computed tomography (CT) or nuclear magnetic resonance imaging are useful in diagnosing neurocysticercosis, they are often too expensive or inaccessible in developing countries. Although some diagnostic tests are currently available to identify *T. solium* infection and diagnose neurocysticercosis, these tests, such as the one described in U.S.

Patent No. 4,740,456 to Kuhn *et al.*, lack specificity and sensitivity. A more specific and sensitive assay for diagnosing human neurocysticercosis by detecting the presence of *T. solium* larvae using immunoelectrotransfer blot (EITB) is described in U.S. Patent No. 5,354,660 to Tsang *et al.*

5 However, the assay utilizes purified, naturally-occurring *T. solium* larval glycoproteins, not recombinantly produced antigens, thereby making the assay reagents expensive and difficult to produce. In developing countries where *T. solium* related diseases are endemic, access to diagnostic assays may be limited due to the high cost of using antigens produced using a

10 complicated purification procedure. Furthermore, because cysticercosis is most prevalent in rural areas of developing countries, a field test is needed for epidemiological studies and surveillance. A field assay would be an important tool in breaking the transmission cycle of the parasite, enabling the on-site diagnosis of infected pigs and immediate treatment with anti-helminthic agents such as oxfendazole. A field diagnosis of cysticercosis

15 would also serve as an economic benefit to pig farmers, because uninfected pigs command a higher price. Therefore there is a need for sensitive, specific, and inexpensive immunoassays containing stable reagents that can detect and measure larval *T. solium* in the clinic, laboratory, and field.

## 20 SUMMARY OF THE INVENTION

Compositions and methods for detecting and diagnosing *Taenia solium* are provided. The compositions contain recombinant or synthetic *T. solium* larval polypeptides. The polypeptides are useful in

25 immunoassays for the detection of larval *T. solium* in biological samples. The polypeptides are recombinantly or synthetically produced larval antigens having the nucleic acid sequences provided herein and molecular weights of approximately 14 kDa, 18 kDa and 21 kDa, as determined by SDS-PAGE analysis, or antigenic fragments thereof. The corresponding,

30 naturally occurring polypeptides are subunits of larger *T. solium* glycoproteins and are referred to herein as TS-14, TS-18 and TSRS-1, respectively.

The 14 kDa recombinant larval polypeptide is preferably encoded by the nucleic acid sequence of SEQ ID NO:1 and has the amino

35 acid sequence of SEQ ID NO:2. The 18 kDa recombinant larval polypeptide is preferably encoded by the nucleic acid sequence of SEQ ID NO:3 and has

the amino acid sequence of SEQ ID NO:4. The 21 kDa recombinant larval polypeptide is preferably encoded by the nucleic acid sequence of SEQ ID NO:5 and has the amino acid sequence of SEQ ID NO:6. Recombinant or synthetic polypeptides having the foregoing amino acid or nucleic acid sequences, or antigenic fragments thereof, are useful in immunoassays for the detection of *T. solium*.

The amino acid sequences provided herein are useful for the synthesis of the antigens or antigenic fragments using well known chemical synthesis techniques.

The nucleic acid molecules encoding the larval antigens are useful for the recombinant production of the antigens and antigen fragments and are also useful as molecular probes or primers for the detection of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) involved in transcription and translation of *T. solium* peptides. These molecular probes or primers provide means to detect and measure *T. solium* larval polypeptides in tissues and cells.

The recombinant or synthetic *T. solium* polypeptides can be used in diagnostic kits to detect the presence and quantity of *T. solium* antibodies, which is diagnostic or prognostic for the occurrence or recurrence of diseases such as cysticercosis and neurocysticercosis. The recombinant *T. solium* polypeptides may also be administered to a human or animal in a pharmaceutical composition to immunize the human or animal against *T. solium* infection, thereby reducing or preventing *T. solium* related disease.

The preferred methods provided herein are immunoassays directed toward the detection of *T. solium* antibodies in biological samples such as biological fluids and tissues of humans and animals. Alternative preferred methods are nucleic acid hybridization or amplification assays directed toward the detection of *T. solium* antigens in biological samples.

In a preferred embodiment, an immunoassay employs one or more of the recombinant or synthetic larval polypeptides, or antigenic fragments thereof, for the detection of anti-larval antibodies in a biological sample. The preferred immunoassay is an immunoblot containing recombinant larval antigens, or antigenic fragments thereof, immunoreactive with anti-*T. solium* antibodies in a biological sample.

Diagnostic and analytical methods and kits may be developed for detection and measurement of *T. solium* antibodies and antigens in a variety of samples. The methods and kits can be in any configuration well known to those of ordinary skill in the art.

5 Accordingly, it is an object of the present invention to provide means for detecting *T. solium* carriers and thus prevent the spread of *T. solium* from one host to another.

10 It is another object of the present invention to provide a method for the detection of *T. solium*, particularly the diagnosis or monitoring of *T. solium* infection in humans and animals, that is inexpensive, sensitive and accurate, with little or no cross-reactivity.

It is another object of the present invention to provide a simple, sensitive method for the diagnosis of cysticercosis or neurocysticercosis.

15 It is yet another object of the present invention to provide a rapid, simple, and inexpensive assay for the detection of *T. solium* larvae that has a long shelf life, a short assay time, and stable reagents that can be utilized in the field, and the results can be interpreted without the use of instrumentation or special temperature conditions, which is optimal for use in poor, underdeveloped countries where *T. solium* is often endemic.

20 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.

## 25 DETAILED DESCRIPTION

Compositions and methods for detecting *T. solium* infection and diagnosing diseases related to *T. solium* infection are provided. The compositions are recombinant or synthetic immunogenic, or immunodominant, polypeptides of the *T. solium* helminth larvae, namely  
30 the polypeptides referred to herein as TS-14, TS-18 and TSRS-1, or antigenic fragments thereof. The nucleic acid sequences and amino acid sequences of the *T. solium* larvae polypeptides are provided.

The recombinant *T. solium* polypeptides are useful as diagnostic reagents in the immunoassays described below. The polypeptides are also useful *in vitro* as research tools for studying *T. solium* in general  
35 and *T. solium* related diseases such as cysticercosis. Additionally, the

polypeptides may be useful in pharmaceutical compositions such as vaccines.

The methods provided herein are assays for the detection or quantitation of anti-*T. solium* antibodies or *T. solium* nucleic acid molecules in a sample such as a human or animal fluid or tissue. The recombinant or synthetic *T. solium* polypeptides, or antigenic fragments thereof, or nucleic acid molecules encoding the *T. solium* polypeptides, or probes and primers thereof, are used as reagents in the assays.

### Definitions

The terms "a", "an" and "the" as used herein are defined to mean "one or more" and include the plural unless the context is inappropriate.

The terms "polypeptide", "peptide", and "protein", as used herein, are interchangeable and are defined to mean a biomolecule composed of two or more amino acids linked by a peptide bond.

The term "antigen" refers to an entity or fragment thereof which can induce an immune response in a mammal. The term includes immunogens and regions responsible for antigenicity or antigenic determinants. "Antigenic determinant" refers to a region of a *T. solium* protein recognized by an antibody.

As used herein, the term "complementary DNA primer" means an oligonucleotide which anneals to a nucleic acid molecule in a particular orientation to allow for the synthesis of a nascent DNA strand in the presence of a polymerase under the conditions described herein. Also as used herein, the "condition" or "conditions" under which a DNA strand is synthesized include the presence of nucleotides, cations and appropriate buffering agents in amounts and at temperatures such that the nucleic acid molecule and the DNA primer will anneal and oligonucleotides will be incorporated into a synthesized DNA strand.

As used herein, the term "primer pair" refers to two primers, one having a forward designation and the other having a reverse designation relative to their respective orientations on a double-stranded DNA molecule which consists of a sense and antisense sequence, such that under the amplification conditions described herein, the forward primer anneals to and primes amplification of the sense sequence and the reverse primer anneals to

and primes amplification of the antisense sequence. Primers can be selected for use in the amplification reaction on the basis of having less than 50% G-C content, having minimal complementarity with other primers in the reaction (to minimize the formation of primer dimers) and having T<sub>m</sub> values with the range of reaction temperatures appropriate for the amplification method, preferably PCR. In addition, primers can be selected to anneal with specific regions of the DNA or RNA template such that the resulting DNA amplification product ranges in size from 100 to 5000 base pairs in length and most preferably around 300 base pairs in length or longer.

As used herein, the terms "detecting" or "detection" refers to quantitatively or quantitatively determining the presence of the biomolecule under investigation.

By "isolated" is meant a biological molecule free from at least some of the components with which it naturally occurs.

By "probe" is meant a nucleic acid sequence that can be used for selective hybridization with complementary nucleic acid sequences for their detection. The probe can vary in length from about 5 to 100 nucleotides, preferably from about 10 to 50 nucleotides, most preferably about 18 to 24 nucleotides. The terms "probe" or "probes" as used herein are defined to include "primers."

The term "antibodies" as used herein includes monoclonal antibodies, polyclonal, chimeric, single chain, bispecific, simianized, and humanized antibodies as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

#### *Taenia solium* Polypeptides and Polypeptide Fragments

The compositions provided herein are recombinant or synthetic *T. solium* larval polypeptides that are immunoreactive with *T. solium* antibodies. *T. solium* antibodies are preferably derived from the sera, saliva, cerebrospinal fluid or urine of patients infected with *T. solium*. Most preferably, the antibodies are derived from *T. solium* patient sera. The recombinant or synthetic polypeptides correspond to naturally occurring glycoproteins having molecular weights of approximately 14 kDa, 18 kDa and 21 kDa. The polypeptides, referred to herein as TS-14, TS-18 and TSRS-1, contain the amino acid sequences provided in the attached Sequence Listing as SEQ ID NOS: 2, 4 and 6, respectively, and are

preferably encoded by the nucleic acid sequences set forth in SEQ ID NOS:1, 3 and 5. It will be understood by those skilled in the art that the preferred polypeptides include polypeptide analogs, which are defined herein as antigenic peptides containing amino acid sequences differing from SEQ ID NOS:2, 4, or 6 by an amino acid substitution at any position or having other molecules attached to amino acid functional groups. The polypeptides are highly charged and polar, and are lysine-rich. The lysine residues contribute to relatively high isoelectric points, 9.25, 8.45 and 8.95 for TS-14, TS-18 and TSRS-1, respectively. TS-14 has one potential N-linked glycosylation site and TS-18 contains three sites. TSRS-1 has one amidation site. The TS-14 and TS-18 polypeptides contain one and two cysteine residues, respectively. The preferred polypeptides also include fragments of the polypeptides having the same antigenicity or the functional equivalent thereof, referred to herein as antigenic fragments. Preferably, the antigenic fragments contain amino acid sequences that are homologous or substantially homologous to two or all three of the antigenic polypeptides. More preferably, the antigenic fragments contain amino acid sequences that are homologous or substantially homologous to TS-14 and TS-18 such as, but not limited to, the following sequences: IAQLAK (SEQ ID NO:7), KNKPKDD/VAASTKKE/GIEYI/VW/HH/R(N)FFF (SEQ ID NO:8), GIEYV/IHE/N(W)FFHE/DD (SEQ ID NO:9). Most preferably, the antigenic fragment contains the amino acid sequence set forth in SEQ ID NO:7.

The *T. solium* polypeptides described herein have a variety of uses. For example the polypeptides or polypeptide fragments are used as reagents in immunoassays for the detection of *T. solium* antibodies as described in more detail below. Furthermore, *T. solium* polypeptides may be employed to develop affinity columns for isolating *T. solium* antibodies. Also, polypeptides that bind to *T. solium* antibodies with high specificity and avidity may be labeled with a label or reporter group and employed for visualization and quantitation in the assays described herein using detection techniques such as autoradiographic and membrane binding techniques. The reporter group or label is commonly a fluorescent or radioactive group or an enzyme. Such applications provide important diagnostic and research tools.

Nucleic Acid Molecules

Nucleic acid molecules encoding the *T. solium* larval polypeptides described above and probes or primers that hybridize to the nucleic acid molecules encoding the *T. solium* larval polypeptides are provided. The preferred nucleic acid molecules are those having sequences encoding the larval *T. solium* polypeptides TS-14, TS-18, and TSRS-1, or fragments thereof, and are provided in the attached Sequence Listing as SEQ ID NOS:1, 3, and 5, respectively. The nucleic acid molecules are useful for production of recombinant polypeptides. Because recombinant methods of polypeptide production produce large quantities of polypeptide that require less purification, recombinant polypeptides are often less expensively produced than polypeptides produced using traditional isolation or purification techniques. The nucleic acid sequences encoding the *T. solium* peptides can be inserted into a vector, such as a plasmid, and recombinantly expressed in a living organism to produce recombinant *T. solium* peptides in accordance with methods well known to those skilled in the art as described in more detail below.

The nucleic acid molecules are also useful as nucleic acid probes or primers for the detection of *T. solium* infection in a biological specimen with high sensitivity and specificity. The probes or primers can be used to amplify or detect *T. solium* larvae nucleic acid molecules in the sample, quantify the amount of *T. solium* in the sample, diagnose infection or determine contamination with *T. solium*, or monitor the progress of therapies used to treat the infection. The nucleic acid molecules described herein are also useful as laboratory research tools to study the organism and the disease and to develop therapies and treatments for the disease.

The nucleic acid probes or primers provided herein selectively hybridize with nucleic acid molecules encoding the peptides described herein or complementary sequences thereof. Hybridization may be achieved under various temperatures and conditions, according to the temperature of dissociation ( $T_d$ ) of the molecules being hybridized and the stringency required for specific binding. The molecules can be hybridized to one another in any order or preferably at the same time. Reaction conditions for hybridization of an oligonucleotide, or polynucleotide, to a nucleic acid sequence vary from oligonucleotide to oligonucleotide, depending on factors such as oligonucleotide length, the number of G and C nucleotides,

and the composition of the buffer utilized in the hybridization reaction. Moderately stringent hybridization conditions are generally understood by those skilled in the art as conditions approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA. Higher specificity is generally achieved by employing incubation conditions having higher temperatures, in other words more stringent conditions. Under extremely stringent hybridization conditions, only oligomers that are completely complementary to each other will remain hybridized to each other. In general, the longer the sequence or higher the G and C content, the higher the temperature required or salt concentration permitted. Chapter 11 of the well-known laboratory manual of Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989), describes hybridization conditions for oligonucleotide probes and primers in great detail, including a description of the factors involved and the level of stringency necessary to guarantee hybridization with specificity.

If used as primers, the composition preferably includes at least two nucleic acid molecules which hybridize to different regions of the target molecule so as to amplify a desired region. Depending on the length of the probe or primer, the target region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions. Preferably, the hybridizing nucleic acid probes or primers described herein have at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, and 99% complementarity with the segment of the sequence to which they hybridize. For the purpose of determining the presence of *T. solium*, the degree of complementarity between the hybridizing nucleic acid (probe or primer) and the sequence to which it hybridizes is at least enough to distinguish hybridization with a nucleic acid from other organisms.

Each probe or primer is preferably a DNA molecule having a length of 20 to 40 nucleotides. More preferably, the length of the primer is 25 to 35 nucleotides. The most preferred primer length is 27 to 29 nucleotides.

The amplification of the synthesized DNA can be detected by any method for the detection of DNA known in the art such as by Southern blot hybridization assay, by visualization of DNA amplification products of specific molecular weight on ethidium bromide stained agarose gels, by

measurement of the incorporation of radiolabelled nucleotides into the synthesized DNA strand by autoradiography or scintillation measurement, by ELISA modified for the capture of a detectable moiety bound to the amplified DNA, or any other detection method known to one of ordinary skill in the art. The preferred detection method is by hybridization of the amplified DNA to an internal specific oligoprobe using techniques such as ELISA, Southern blot hybridization or similar methods.

The invention contemplates sequences, probes and primers which selectively hybridize to the encoding nucleic acid or the complementary, or opposite, strand of nucleic acid as those specifically provided herein. Specific hybridization with nucleic acid can occur with minor modifications or substitutions in the nucleic acid, so long as functional species-specific hybridization capability is maintained. Isolated nucleic acids are provided herein that selectively hybridize with the nucleic acids encoding the polypeptides under stringent conditions and should have at least five nucleotides complementary to the sequence of interest as described by Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

It will be understood by those skilled in the art that the *T. solium* polypeptides described herein are also encoded by sequences substantially similar to the nucleic acid sequences provided in the Sequence Listing. By "substantially similar" is meant a nucleic acid (including DNA and RNA) sequence which, by virtue of the degeneracy of the genetic code, is not identical with that shown in any of SEQ ID NOS:1, 3 or 5, but which still encodes the same amino acid sequence; or a nucleic acid sequence which encodes a different amino acid sequence but retains the activities or antigenicity of the proteins, either because one amino acid is replaced with another similar amino acid, or because the change (whether it be substitution, deletion or insertion) does not effect the active site of the protein.

#### Production of Synthetic or *T. solium* Larvae Polypeptides

The nucleic acid sequences provided herein are useful for the production of the proteins or peptides that they encode, or antigenic fragments thereof, by either recombinant or synthetic methods known to

those skilled in the art. For example, one or more of the nucleotide sequence provided herein, or a homologue or functional equivalent or portion thereof, can be inserted into a vector, such as a plasmid, and recombinantly expressed in a living organism to produce recombinant polypeptides. Alternatively, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, PROTEINS STRUCTURES AND MOLECULAR PRINCIPLES, W. H. Freeman and Co., N.Y. pp. 50-60). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequence (e.g., the Edman degradation procedure; see Creighton, 1983, PROTEINS, STRUCTURES AND MOLECULAR PRINCIPLES, W. H. Freeman and Co., N.Y., pp. 34-49).

Recombinant proteins are produced by methods well known to those skilled in the art. A cloning vector, such as a plasmid or phage DNA is cleaved with a restriction enzyme, and the nucleic acid sequence encoding the proteins or fragments thereof of interest is inserted into the cleavage site and ligated. The cloning vector is then inserted into a host to produce the protein or fragment encoded by the nucleic acid. Suitable hosts include bacterial hosts such as *Escherichia coli*, *Bacillus subtilis*, yeasts plants, baculovirus, and other cell cultures. Yeasts are the preferred hosts for vaccine or pharmaceutical product expression. Production and purification of the gene product may be achieved and enhanced using known molecular biology techniques. Mosaic peptides may also be produced by combining various nucleic acid sequences in a cloning vector.

Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, GUIDE TO MOLECULAR CLONING TECHNIQUES, METHODS IN ENZYMOLOGY volume 152 Academic Press, Inc., San Diego, CA; Sambrook *et al.* (1989) MOLECULAR CLONING - A LABORATORY MANUAL (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement). Product information from manufacturers of biological reagents and experimental equipment also provide information useful in known biological

methods. Such manufacturers include the SIGMA Chemical Company (Saint Louis, MO), R&D Systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ), CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersburg, MD), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), Invitrogen (Carlsbad, CA), and Applied Biosystems (Foster City, CA), as well as many other commercial sources known to one of skill.

Provided with the peptide sequences described herein, one of skill will recognize a variety of equivalent nucleic acids that encode the peptides. This is because the genetic code requires that each amino acid residue in a peptide is specified by at least one triplet of nucleotides in a nucleic acid which encodes the peptide. Due to the degeneracy of the genetic code, many amino acids are equivalently coded by more than one triplet of nucleotides. For instance, the triplets CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is to be encoded by a nucleic acid triplet, the nucleic acid has any of the triplets which encode arginine. One of skill is thoroughly familiar with the genetic code and its use. An introduction to the subject is found in, for example, chapter 15 of Watson, *et al.*, MOLECULAR BIOLOGY OF THE GENE (Fourth Edition, The Benjamin/Cummings Company, Inc., Menlo Park, CA (1987)), and the references cited therein.

Although any nucleic acid triplet or codon which encodes an amino acid can be used to specify the position of the amino acid in a peptide, certain codons are preferred. It is desirable to select codons for elevated expression of an encoded peptide, for example, when the peptide is purified for use as an immunogenic reagent. Codons are selected by reference to species codon bias tables, which show which codons are most typically used by the organism in which the peptide is to be expressed. The codons used frequently by an organism are translated by the more abundant t-RNAs in the cells of the organism. Because the t-RNAs are abundant, translation of the nucleic acid into a peptide by the cellular translation machinery is facilitated. Codon bias tables are available for most organisms. For an introduction to codon bias tables, *see, e.g., Watson, et al., supra.*

In addition, it will be readily apparent to those of ordinary skill in the art that the peptides described herein and the nucleic acid molecules encoding such immunogenic peptides can be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, *i.e.*, to increase biological activity.

One of skill will appreciate that many conservative variations of nucleic acid constructs yield a functionally identical construct. For example, due to the degeneracy of the genetic code, silent substitutions (*i.e.*, substitutions of a nucleic acid sequence which do not result in an alteration in an encoded peptide) are an implied feature of *every* nucleic acid sequence which encodes an amino acid. In addition, one of skill will recognize many ways of generating alterations in a given nucleic acid construct. Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (*e.g.*, in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques. *See*, Gilman and Smith (1979) *Gene* 8:81-97, Roberts *et al.* (1987) *Nature* 328:731-734 and Sambrook, Ausbel, Berger and Kimmel, *all supra*.

Modifications to nucleic acids are evaluated by routine screening techniques in suitable assays for the desired characteristic. For instance, changes in the immunological character of encoded peptides can be detected by an appropriate immunological assay. Modifications of other properties such as nucleic acid hybridization to a complementary nucleic acid, redox or thermal stability of encoded proteins, hydrophobicity, susceptibility to proteolysis, or the tendency to aggregate are all assayed according to standard techniques.

Similarly, conservative amino acid substitutions, in one or a few amino acids in an amino acid sequence of a protein are substituted with different amino acids with highly similar properties (*see*, the definitions section, *supra*), are also readily identified as being highly similar to a disclosed construct. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, *e.g.*, one hydrophobic residue for another, or one polar residue for

another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are a feature of the present invention.

5                   Various techniques for preparing synthetic polypeptides can be used. Solid phase synthesis in which the C-terminal amino acid of the peptide sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is the preferred method for preparing the synthetic peptides. Techniques for solid phase  
10 synthesis are described by Barany and Merrifield, *Solid-Phase Peptide Synthesis*, in *The Peptides: Analysis, Synthesis, Biology* (Gross and Meienhofer (eds.), Academic Press, N.Y., vol. 2, pp. 3-284 (1980)); Merrifield, *et al.*, *J. Am. Chem. Soc.* 85, 2149-2156 (1963); and Stewart,  
15 *et al.*, *Solid Phase Peptide Synthesis* (2nd ed., Pierce Chem. Co., Rockford, Ill. (1984)), the teachings of which are hereby incorporated by reference. Many automated systems for performing solid phase peptide synthesis are commercially available.

                  Solid phase synthesis is started from the carboxy-terminal end (*i.e.*, the C-terminus) of the peptide by coupling a protected amino acid  
20 via its carboxyl group to a suitable solid support. The solid support used is not a critical feature of the present invention provided that it is capable of binding to the carboxyl group while remaining substantially inert to the reagents utilized in the peptide synthesis procedure. For example, a starting material can be prepared by attaching an amino-protected amino acid via a  
25 benzyl ester linkage to a chloromethylated resin or a hydroxymethyl resin or via an amide bond to a benzhydrylamine (BHA) resin or p-methylbenzhydrylamine (MBHA) resin. Materials suitable for use as solid supports are well known to those of skill in the art and include, but are not limited to, the following: halomethyl resins, such as chloromethyl resin or  
30 bromomethyl resin; hydroxymethyl resins; phenol resins, such as 4-(a-[2,4-dimethoxyphenyl]-Fmoc-aminomethyl)phenoxy resin; tert-alkyloxycarbonyl-hydrazidated resins, and the like. Such resins are commercially available and their methods of preparation are known to those of ordinary skill in the art.

35                   The acid form of the peptides may be prepared by the solid phase peptide synthesis procedure using a benzyl ester resin as a solid

support. The corresponding amides may be produced by using benzhydrylamine or methylbenz-hydrylamine resin as the solid support. Those skilled in the art will recognize that when the BHA or MBHA resin is used, treatment with anhydrous hydrofluoric acid to cleave the peptide from the solid support produces a peptide having a terminal amide group.

The  $\alpha$ -amino group of each amino acid used in the synthesis should be protected during the coupling reaction to prevent side reactions involving the reactive  $\alpha$ -amino function. Certain amino acids also contain reactive side-chain functional groups (*e.g.*, sulfhydryl, amino, carboxyl, hydroxyl, *etc.*) which must also be protected with appropriate protecting groups to prevent chemical reactions from occurring at those sites during the peptide synthesis. Protecting groups are well known to those of skill in the art.

A properly selected  $\alpha$ -amino protecting group will render the  $\alpha$ -amino function inert during the coupling reaction, will be readily removable after coupling under conditions that will not remove side chain protecting groups, will not alter the structure of the peptide fragment, and will prevent racemization upon activation immediately prior to coupling. Similarly, side-chain protecting groups must be chosen to render the side chain functional group inert during the synthesis, must be stable under the conditions used to remove the  $\alpha$ -amino protecting group, and must be removable after completion of the peptide synthesis under conditions that will not alter the structure of the peptide.

Coupling of the amino acids may be accomplished by a variety of techniques known to those of skill in the art. Typical approaches involve either the conversion of the amino acid to a derivative that will render the carboxyl group more susceptible to reaction with the free N-terminal amino group of the peptide fragment, or use of a suitable coupling agent such as, for example, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIPCDI). Frequently, hydroxybenzotriazole (HOBt) is employed as a catalyst in these coupling reactions. Appropriate synthesis chemistries are disclosed in THE PEPTIDES: ANALYSIS, STRUCTURE, BIOLOGY, VOL. 1: METHODS OF PEPTIDE BOND FORMATION (Gross and Meienhofer (eds.), Academic Press, N.Y. (1979)); and Izumiya, *et al.*, SYNTHESIS OF PEPTIDES (Maruzen Publishing Co., Ltd., (1975)).

Generally, synthesis of the peptide is commenced by first coupling the C-terminal amino acid, which is protected at the N-amino position by a protecting group such as fluorenylmethyloxycarbonyl (Fmoc), to a solid support. Prior to coupling of Fmoc-Asn, the Fmoc residue has to be removed from the polymer. Fmoc-Asn can, for example, be coupled to the 4-(a-[2,4-dimethoxyphenyl]-Fmoc-amino-methyl)phenoxy resin using N,N'-dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt) at about 25°C for about two hours with stirring. Following the coupling of the Fmoc-protected amino acid to the resin support, the  $\alpha$ -amino protecting group is removed using 20% piperidine in DMF at room temperature.

After removal of the  $\alpha$ -amino protecting group, the remaining Fmoc-protected amino acids are coupled stepwise in the desired order. Appropriately protected amino acids are commercially available from a number of suppliers (*e.g.*, Novartis (Switzerland) or Bachem (California)). As an alternative to the stepwise addition of individual amino acids, appropriately protected peptide fragments consisting of more than one amino acid may also be coupled to the "growing" peptide. Selection of an appropriate coupling reagent, as explained above, is well known to those of skill in the art. It should be noted that because the immunogenic peptides are relative short in length, this latter approach (*i.e.*, the segment condensation method) is not the most efficient method of peptide synthesis.

Each protected amino acid or amino acid sequence is introduced into the solid phase reactor in excess and the coupling is carried out in a medium of dimethylformamide (DMF), methylene chloride ( $\text{CH}_2\text{Cl}_2$ ), or mixtures thereof. If coupling is incomplete, the coupling reaction may be repeated before deprotection of the N-amino group and addition of the next amino acid. Coupling efficiency may be monitored by a number of means well known to those of skill in the art. A preferred method of monitoring coupling efficiency is by the ninhydrin reaction. Peptide synthesis reactions may be performed automatically using a number of commercially available peptide synthesizers (*e.g.*, Biosearch 9500, Biosearch, San Raphael, CA).

The peptide can be cleaved and the protecting groups removed by stirring the insoluble carrier or solid support in anhydrous, liquid hydrogen fluoride (HF) in the presence of anisole and dimethylsulfide at about 0°C for about 20 to 90 minutes, preferably 60 minutes; by bubbling

hydrogen bromide (HBr) continuously through a 1 mg/10 mL suspension of the resin in trifluoroacetic acid (TFA) for 60 to 360 minutes at about room temperature, depending on the protecting groups selected; or by incubating the solid support inside the reaction column used for the solid phase synthesis with 90% trifluoroacetic acid, 5% water and 5% triethylsilane for about 30 to 60 minutes. Other deprotection methods well known to those of skill in the art may also be used.

The peptides can be isolated and purified from the reaction mixture by means of peptide purification well known to those of skill in the art. For example, the peptides may be purified using known chromatographic procedures such as reverse phase HPLC, gel permeation, ion exchange, size exclusion, affinity, partition, or countercurrent distribution.

#### Labeled Polypeptides

When labeled with a detectable biomolecule or chemical, the *T. solium* polypeptides and antigenic fragments thereof described above are useful for purposes such as diagnostics and laboratory research using the methods and assays described below. Various types of labels and methods of conjugating the labels to the polypeptides are well known to those skilled in the art. Several specific labels are set forth below.

For example, the polypeptides are conjugated to a radiolabel such as, but not restricted to,  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ , or  $^{131}\text{I}$ . Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography.

Bioluminescent labels, such as derivatives of firefly luciferin, are also useful. The bioluminescent substance is covalently bound to the polypeptide by conventional methods, and the labeled polypeptide is detected when an enzyme, such as luciferase, catalyzes a reaction with ATP causing the bioluminescent molecule to emit photons of light.

Fluorogens may also be used as labels. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycoyanin, phycocyanin, rhodamine, and Texas Red. The fluorogens are generally detected by a fluorescence detector.

The polypeptides can alternatively be labeled with a chromogen to provide an enzyme or affinity label. For example, the

polypeptide can be biotinylated so that it can be utilized in a biotin-avidin reaction, which may also be coupled to a label such as an enzyme or fluorogen. Alternatively, the polypeptide can be labeled with peroxidase, alkaline phosphatase or other enzymes giving a chromogenic or fluorogenic reaction upon addition of substrate. Additives such as 5-amino-2,3-dihydro-1,4-phthalazinedione (also known as Luminol™) (Sigma Chemical Company, St. Louis, MO) and rate enhancers such as p-hydroxybiphenyl (also known as p-phenylphenol) (Sigma Chemical Company, St. Louis, MO) can be used to amplify enzymes such as horseradish peroxidase through a luminescent reaction; and luminogenic or fluorogenic dioxetane derivatives of enzyme substrates can also be used. Such labels can be detected using enzyme-linked immunoassays (ELISA) or by detecting a color change with the aid of a spectrophotometer. In addition, peptides may be labeled with colloidal gold for use in immunoelectron microscopy in accordance with methods well known to those skilled in the art.

The diagnosis of an infection by *T. solium* larvae can be determined by labeling a polypeptide as described above and detecting the label in accordance with methods well known to those skilled in the art.

#### Detection of *T. solium* Antibodies

Many techniques are known in the art for detecting and quantifying a component such as an antibody in a mixture and/or measuring its amount. Immunoassays, which employ polypeptides that bind specifically to the antibodies of interest, are some of the better known measurement techniques. These methods permit detection of circulating *T. solium* antibodies in order to indicate the presence or level of *T. solium* infection. Classical methods involve reacting a sample containing the antibody with a known excess amount of polypeptide specific for the antibody, separating bound from free antibody, and determining the amount of one or the other. Often the polypeptide is labeled with a reporter group to aid in the determination of the amount of bound analyte as described above. The reporter group or "label" is commonly a fluorescent or radioactive group or an enzyme.

In a preferred embodiment of the present invention, the diagnostic method comprises using an immunoblot assay. In a further preferred embodiment, the diagnostic method is an immunoblot assay

## 20

containing one or more of the larval *T. solium* glycoprotein antigens referred to herein as TS-14, TS-18 and TSRS-1, or antigenic fragments thereof. As mentioned above, these polypeptides have the amino acid sequences set forth in the Sequence Listing as SEQ ID NOS: 2, 4 and 6, respectively, and are encoded by the nucleic acid sequences set forth in the Sequence Listing as SEQ ID NOS: 1, 3, 5.

It is to be understood that the assay methods are contemplated to include the use of synthetic and recombinant *T. solium* polypeptides as described above and fragments or derivatives of the *T. solium* polypeptides described herein as long as the polypeptide fragments or derivatives retain antigenic activity or display an equivalent antigenic activity of the entire immunogenic polypeptides. These fragments or derivatives include peptides with antigenic activity that have amino acid substitutions or have other molecules attached to amino acid functional groups.

An immunoassay is performed for the detection of *T. solium* in a sample as follows: A sample is collected or obtained using methods well known to those skilled in the art. The sample containing the *T. solium* antibodies to be detected may be obtained from any biological source. Examples of biological sources include blood serum, blood plasma, urine, spinal fluid, saliva, fermentation fluid, lymph fluid, tissue culture fluid and ascites fluid of a human or animal. The sample may be diluted, purified, concentrated, filtered, dissolved, suspended or otherwise manipulated prior to immunoassay to optimize the immunoassay results.

To detect *T. solium* antibodies, the sample is incubated with one or more *T. solium* recombinant or synthetic polypeptides, produced as described above. The polypeptide may be labeled or conjugated to a solid phase bead or particle as also described herein. The labeled polypeptide is then detected using well known techniques for detection of biologic molecules such as immunochemical or histological methods. Such methods include immunological techniques employing monoclonal or polyclonal antibodies to the polypeptide, such as enzyme linked immunosorbant assays, radioimmunoassay, chemiluminescent assays, or other types of assays involving antibodies known to those skilled in the art.

In general, binding assays rely on the binding of analyte by analyte receptors to determine the concentrations of analyte in a sample.

## 21

These immunoassays can be described as either competitive or non-competitive. Non-competitive assays generally utilize analyte receptors in substantial excess over the concentration of analyte to be determined in the assay. Sandwich assays are examples of non-competitive assays, that  
5 comprise one analyte receptor frequently bound to a solid phase and a second analyte receptor labeled to permit detection. The analyte first binds to the analyte receptor bound to a solid phase and the second labeled analyte receptor is then added to facilitate quantitation of the analyte. Bound analyte can easily be separated from unbound reagents, such as unbound labeled  
10 first analyte receptors, due to the use of an analyte receptor bound to a solid phase. Competitive assays generally involve a sample suspected of containing analyte, an analyte-analogue conjugate, and the competition of these species for a limited number of binding sites provided by the analyte receptor. Competitive assays can be further described as being either  
15 homogeneous or heterogeneous. In homogeneous assays all of the reactants participating in the competition are mixed together and the quantity of analyte is determined by its effect on the extent of binding between analyte receptor and analyte-conjugate or analyte analogue-conjugate. The signal observed is modulated by the extent of this binding and can be related  
20 to the amount of analyte in the sample.

In a preferred embodiment, the method for detecting larval *T. solium* antibodies comprises taking biological samples, such as fluids and tissues, from a human or animal for the diagnosis or prognosis of cysticercosis. The sample is preferably obtained from the blood,  
25 cerebrospinal fluid, urine, saliva, or tissues of a mammal, preferably a human or pig. A determination of the presence of the antibodies can then be made using assay techniques that are well known to those skilled in the art and include methods such as Western blot analysis, radioimmunoassay and ELISA assays.

30

Kit for Detecting the Presence of *T. solium*

A kit for detecting the presence and quantity of *T. solium* peptides is also provided. The kit can be in any configuration well known to those of ordinary skill in the art and is useful performing one or more of the  
35 methods described herein for the detection of *T. solium* in biological samples or for the detection or monitoring of *T. solium* infection in a patient

or carrier. The kits are convenient in that they supply many if not all of the essential reagents for conducting an assay for the detection of *T. solium* in a biological sample. The reagents may be premeasured and contained in a stable form in vessels or on a solid phase in or on which the assay may be performed, thereby minimizing the number of manipulations carried out by the individual conducting the assay. In addition, the assay may be performed simultaneously with a standard that is included with the kit, such as a predetermined amount of antigen or antibody, so that the results of the test can be validated or measured.

The kit preferably contains one or more *T. solium* polypeptides or nucleic acid molecules that can be used for the detection of *T. solium* antibodies or nucleic acid molecules in a sample. The kit can additionally contain the appropriate reagents for binding the polypeptides to the antibodies or hybridizing the nucleic acid molecules to their respective *T. solium* complementary nucleic acid molecules in the sample as described herein and reagents that aid in detecting the antibody-polypeptide or nucleic acid molecule complexes. The kit may additionally contain equipment for safely obtaining the sample, a vessel for containing the reagents, a timing means, a buffer for diluting the sample, and a colorimeter, reflectometer, or standard against which a color change may be measured.

In a preferred embodiment, the reagents, including the polypeptides, are lyophilized, most preferably in a single vessel. Addition of aqueous sample to the vessel results in solubilization of the lyophilized reagents, causing them to react. Most preferably, the reagents are sequentially lyophilized in a single container, in accordance with methods well known to those skilled in the art that minimize reaction by the reagents prior to addition of the sample.

The assay kit includes but is not limited to reagents to be employed in the following techniques; competitive and non-competitive assays, radioimmunoassay, bioluminescence and chemiluminescence assays, fluorometric assays, sandwich assays, immunoradiometric assays, dot blots, enzyme linked assays including immunoblots and ELISAs, and immunocytochemistry. Materials used in conjunction with these techniques include, but are not limited to, microtiter plates, antibody coated strips or dipsticks for rapid monitoring of urine or blood. For each kit, the range,

sensitivity, precision, reliability, specificity and reproducibility of the assay are established.

In a further preferred embodiment, the assay kit uses immunoblot techniques and provides instructions and recombinant larval *T. solium* polypeptides conjugated to a detectable molecule. The kit is useful for the detection and measurement of *T. solium* in biological fluids and tissue extracts of animals and humans to diagnose or monitor cysticercosis or neurocysticercosis.

#### Immunological and Pharmaceutical Compositions

Immunological compositions, including vaccine, and other pharmaceutical compositions containing the *T. solium* polypeptides or antigenic fragments thereof described herein are useful for reducing or possibly preventing *T. solium* infection or transmission. One or more of the polypeptides described herein are formulated and packaged, alone or in combination with adjuvants or other antigens, using methods and materials known to those skilled in the vaccine art. The immunological response may be used therapeutically or prophylactically and may provide antibody immunity or cellular immunity such as that produced by T lymphocytes such as cytotoxic T lymphocytes or CD4<sup>+</sup> T lymphocytes.

To enhance immunogenicity, one or more of the polypeptides may be conjugated to a carrier molecule. Suitable immunogenic carriers include proteins, polypeptides or peptides such as albumin, hemocyanin, thyroglobulin and derivatives thereof, particularly bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH), polysaccharides, carbohydrates, polymers, and solid phases. Other protein derived or non-protein derived substances are known to those skilled in the art. An immunogenic carrier typically has a molecular weight of at least 1,000 daltons, preferably greater than 10,000 daltons. Carrier molecules often contain a reactive group to facilitate covalent conjugation to the hapten. The carboxylic acid group or amine group of amino acids or the sugar groups of glycoproteins are often used in this manner. Carriers lacking such groups can often be reacted with an appropriate chemical to produce them. Alternatively, a multiple antigenic polypeptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically

equivalent polypeptide may be sufficiently antigenic to improve immunogenicity without the use of a carrier.

The *T. solium* polypeptides may be administered with an adjuvant in an amount effective to enhance the immunogenic response against the conjugate. At this time, the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide). Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have toxicities which limit their potential use in human vaccines. However, chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff *et al. J. Immunol.* 147:410-415 (1991), encapsulation of the conjugate within a proteoliposome as described by Miller *et al., J. Exp. Med.* 176:1739-1744 (1992), and encapsulation of the protein in lipid vesicles may also be useful.

The term "vaccine" as used herein includes DNA vaccines in which the nucleic acid molecule encoding *T. solium* polypeptides in a pharmaceutical composition is administered to a patient. For genetic immunization, suitable delivery methods known to those skilled in the art include direct injection of plasmid DNA into muscles (Wolff *et al., Hum. Mol. Genet.* 1:363 (1992)), delivery of DNA complexed with specific protein carriers (Wu *et al., J. Biol. Chem.* 264:16985 (1989)), coprecipitation of DNA with calcium phosphate (Benvenisty and Reshef, *Proc. Natl. Acad. Sci.* 83:9551 (1986)), encapsulation of DNA in liposomes (Kaneda *et al., Science* 243:375 (1989)), particle bombardment (Tang *et al., Nature* 356:152 (1992) and (Eisenbraun *et al., DNA Cell Biol.* 12:791 (1993)), and *in vivo* infection using cloned retroviral vectors (Seeger *et al., Proc. Natl. Acad. Sci.* 81:5849 (1984)).

In a preferred embodiment, a vaccine is packaged in a single dosage for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration. The vaccine is most preferably injected intramuscularly into the deltoid muscle. The vaccine is preferably combined with a pharmaceutically acceptable carrier to facilitate administration. The carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for resuspension at the time of administration or in solution.

The carrier to which the polypeptide may be conjugated may also be a polymeric delayed release system. Synthetic polymers are particularly useful in the formulation of a vaccine to effect the controlled release of antigens.

5 Microencapsulation of the polypeptide will also give a controlled release. A number of factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered. Examples of useful polymers are polycarbonates, polyesters, polyurethanes, polyorthoesters polyamides, poly (d,l-lactide-co-glycolide) (PLGA) and other biodegradable polymers.

10 The preferred dose for human administration of the pharmaceutical composition or vaccine is from 0.01 mg/kg to 10 mg/kg, preferably approximately 1 mg/kg. Based on this range, equivalent dosages for heavier body weights can be determined. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The vaccine may additionally contain stabilizers such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, MO) or physiologically acceptable preservatives.

25 This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

## 26

**Example 1***Expression and Analysis of the 14 and 18 kDa T. solium  
Polypeptides*

5                   The coding regions for the mature TS-14 and TS-18  
polypeptides, set forth in SEQ ID NOS: 1 and 3, were subcloned into the  
expression vector pET-32 and expressed in *E. coli* as thioredoxin fusion  
proteins. After induction of expression, the total bacterial lysate was  
10                   analyzed by immunoblot. Total *E. coli* TS-14 and TS-18 proteins from  
induced cultures were resolved on SDS-PAGE, blotted onto nitrocellulose,  
and probed with cysticercosis infection sera, an anti-thioredoxin monoclonal  
antibody (Invitrogen, Carlsbad, CA), antibodies from a serum sample from  
an Alaskan native who had an *Echinococcus multilocularis*, and antibodies  
15                   from a serum pool containing sera from healthy humans residing in the  
U.S. with no history of travel. Induced recombinant protein from the  
plasmid lacking an insert and encoding only the thioredoxin tag was only  
recognized by the anti-thioredoxin monoclonal antibody and migrated at 20  
kDa. Anti-cysticercosis antibodies specifically recognized the TS-14 and  
20                   TS-18 recombinant proteins, which both migrated in SDS-PAGE with a  
predicted molecular weight of 28 kDa due to the thioredoxin tag. Neither  
subunit reacted with antibodies from the echinococcosis infection serum or  
the uninfected serum pool, thereby indicating a lack of cross-reactivity. In  
comparing the relative protein concentrations, determined by aurodye  
25                   staining and by reactivity with the anti-thioredoxin monoclonal antibody,  
and anti-cysticercosis reactivity of the 14- and 18-kDa recombinant proteins,  
it appears that the 14-kDa recombinant protein is more reactive with anti-  
cysticercosis antibodies, consistent with earlier observations of the native  
antigen.

30                   All of the patents, publications and other references  
mentioned herein are hereby incorporated by reference.

35                   Modifications and variations of the present method will be  
obvious to those skilled in the art from the foregoing detailed description.  
Such modifications and variations are intended to come within the scope of  
the appended claims.

## CLAIMS

We claim:

- 5                   1.       A composition comprising one or more isolated, synthetic or recombinant larval *T. solium* polypeptides or antigenic fragments thereof, immunoreactive with *T. solium* antibodies.
- 10                   2.       The composition of Claim 1 wherein the polypeptides are selected from the group consisting of TS-14, TS-18 and TSRS-1.
- 15                   3.       The composition of Claim 1 wherein the polypeptides have amino acid sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.
4.       The composition of Claim 1 wherein the polypeptide fragment contains the amino acid sequence set forth in SEQ ID NO:7.
- 20                   5.       The composition of Claim 1 wherein the polypeptides are encoded by nucleic acid molecules having nucleic acid sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
- 25                   6.       An isolated nucleic acid molecule having a sequence encoding a larval *Taenia solium* polypeptide, wherein the nucleic acid sequence encodes a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.
- 30                   7.       An isolated nucleic acid molecule having a sequence encoding a larval *Taenia solium* polypeptide, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.
- 35                   8.       A method for detecting *T. solium* antibodies in an biological sample comprising combining the sample with one or more recombinant or

synthetic larval *Taenia solium* polypeptides, or antigenic fragments thereof, immunoreactive with *T. solium* antibodies and detecting the formation of a complex between the polypeptides or fragments thereof and antibodies in the sample, wherein the presence of an antibody-polypeptide complex indicates the presence of *T. solium* antibodies in the sample.

9. The method of Claim 8 wherein the polypeptides are selected from the group consisting of TS-14, TS-18 and TSRS-1.

10. The method of Claim 8 wherein the polypeptides have amino acid sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

11. The method of Claim 8 wherein the polypeptide fragment contains the amino acid sequence set forth in SEQ ID NO:7.

12. The method of Claim 8 wherein the polypeptides are encoded by nucleic acid molecules having nucleic acid sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.

13. A method for diagnosing cysticercosis in a mammal comprising contacting a biological sample of the mammal with one or more synthetic or recombinant larval *Taenia solium* polypeptides, or antigenic fragments thereof, immunoreactive with *T. solium* antibodies, and detecting the binding of antibody present in the biological sample to a *Taenia solium* glycoprotein antigen, wherein the detection of binding indicates cysticercosis.

14. The method of Claim 13 wherein the polypeptides have an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

15. The method of Claim 13 wherein the polypeptide fragment contains the amino acid sequence set forth in SEQ ID NO:7.

## 29

16. The method of Claim 13, wherein the polypeptides are encoded by nucleic acid molecules having nucleic acid sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.

## SEQUENCE LISTING

<110> Tsang, Victor C. W.  
Greene, Ryan M.  
Wilkins, Patricia P.  
Hancock, Kathy

<120> Methods and Compositions for Detecting Taenia Solium

<130> 03063-0551WP

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 2153

<212> DNA

<213> Taenia solium

<220>

<221> CDS

<222> (145)..(531)

<400> 1

```

ctgcagtgaa gttgacaagt agttgaccat ttacggaaca tcaatggagg acacttttgt 60
agggaaagca tacgataaac ataaaccaat gctgggttata taagagacga tctcggctac 120
acttgtaact gaacaacctg taga atg cgt gcc tac att gtg ctt ctc gct 171
                Met Arg Ala Tyr Ile Val Leu Leu Ala
                  1                      5

ctc act gtt ttc gta gtg acg gtg tcg gcc gag tgg gtg ccc att tcg 219
Leu Thr Val Phe Val Val Thr Val Ser Ala Glu Trp Val Pro Ile Ser
  10                      15                      20                      25

agt gtc cac ata gcc tca tgc aaa agc cac tac atg ttc caa tta aaa 267
Ser Val His Ile Ala Ser Cys Lys Ser His Tyr Met Phe Gln Leu Lys
                30                      35                      40

cgc ttt ttt gcc ttt agg aaa aac aaa ccg aaa gat gtt gca aat agt 315
Arg Phe Phe Ala Phe Arg Lys Asn Lys Pro Lys Asp Val Ala Asn Ser
                45                      50                      55

acg aaa aaa ggg ata gaa tat gtc cac gaa ttc ttc cac gaa gac ccg 363
Thr Lys Lys Gly Ile Glu Tyr Val His Glu Phe Phe His Glu Asp Pro
                60                      65                      70

att ggt aaa caa att gct caa ctc gca aag gaa tgg aag gaa gca atg 411
Ile Gly Lys Gln Ile Ala Gln Leu Ala Lys Glu Trp Lys Glu Ala Met
  75                      80                      85

ttg gaa ggt agg ttt tgg tgt ttt ctg tca gaa gaa aat tat cta ttc 459
Leu Glu Gly Arg Phe Trp Cys Phe Leu Ser Glu Glu Asn Tyr Leu Phe

```

90	95	100	105	
att cat cta gac aaa ggc aaa ata cgg acg tca ctg gtt gag cac tgc				507
Ile His Leu Asp Lys Gly Lys Ile Arg Thr Ser Leu Val Glu His Cys				
	110	115	120	
aaa ggt cct aag aaa aaa act gct taacttgtca actttcatgc gttcttctct				561
Lys Gly Pro Lys Lys Lys Thr Ala				
	125			
tcactaataa atgctcatta ataagaaagc tgccttttgc aagatcaacg agggccatag				621
actgtgaggg ttatagccta aggttatggg gtgaaatgag ataggaattg agcatttgag				681
aagttactaa tttaaattga aagccgcatt tcttctgcaa ttgacgtgtg atggttagcg				741
aaaccaagtg aagcacgacc tcttgagtcg tttcaacagc cgccagtggg ttcaccagtg				801
gcttcaccag tgggtagact ggtttgtcac acatgcgagg tacggtcaga gggctaacag				861
gtgtgggtgga ggggccaaca cgtgtaagac aagcagttcc ctttctctgt cgtgaggcac				921
actcagcacc cacctcgttt acttctccct tgacgactgt aatgcatttg gggtcaccat				981
gccccgcga agttgaaggc actgatgaca tttgtaccat atcaccgata agtattaact				1041
cttcacttc ccagattttg aggtcaggcg atcctactga ctcggtgtag ccccatgggtg				1101
gtccatgctc tgcaccattc gctgttcagt ggagcatcca cctagacggc caaccaatct				1161
cgctccctt ctctgtgct caagatgtgc gtcggtgaga tttggagggt ctgatcacca				1221
tactaaccac gtaggtttca tcatctctaa gaagcaccac ttcttgaggt cgcattgtgt				1281
accaccagcc ggtgtaatca agagtgactt tcgcgtcacc cctaagaagg ctatagatct				1341
gcaagtcagc gcaatagctt cagccatgct gactaaaatg tgtaagggaac cagtagctct				1401
agcccaacac aagtggagct aataatgggc ttccccagat acatgaatcc caaatcggtg				1461
agcatgggcc atgaatatgg ctttctgagt cttccttgaa tgcaaacgaa ggcatagcac				1521
gagggtagga tgagtgtaca gaaaacagcg aggcaacgaa tctactggca tggccctgat				1581
gccacccgc ccagctaggg tagtttgagg acctcagtcc ttaatcgaat gcggcagtca				1641
gaacaaacaa agtattacat agccacactc ttcttttgag cgtcgtcctc gacgtcctt				1701
tcgacacacc tcccgcatca gccaccacaa agtaatcagt actggggaga caccacgag				1761
ctaaccgtgc cagtcatgga aaatttgacg gcaactgagg agatgcctga ccccttttg				1821
cagttcgaat gctgcccgtg gtcaaactcc tgcacagcc atcacctacg attcaaacat				1881
cctagtcgcc aaattttcgt gaacctctaa aaattttcgt gcactctcaa gacacttcca				1941
actgacttag agctttttca tttgggtgaga acacgtaaaa gcttcaagta aacaacaggc				2001
aacgatttca ctttgatgct ctcaccatca attctcttgt atgtgccacc accttaaacc				2061

ctccctgacc acttcactc tctctctctc cctaaataac aacacttgga agcatgaatg 2121  
 gtgtctgtca aagttacacc cctagactgc ag 2153

<210> 2  
 <211> 129  
 <212> PRT  
 <213> Taenia solium

<400> 2  
 Met Arg Ala Tyr Ile Val Leu Leu Ala Leu Thr Val Phe Val Val Thr  
 1 5 10 15  
 Val Ser Ala Glu Trp Val Pro Ile Ser Ser Val His Ile Ala Ser Cys  
 20 25 30  
 Lys Ser His Tyr Met Phe Gln Leu Lys Arg Phe Phe Ala Phe Arg Lys  
 35 40 45  
 Asn Lys Pro Lys Asp Val Ala Asn Ser Thr Lys Lys Gly Ile Glu Tyr  
 50 55 60  
 Val His Glu Phe Phe His Glu Asp Pro Ile Gly Lys Gln Ile Ala Gln  
 65 70 75 80  
 Leu Ala Lys Glu Trp Lys Glu Ala Met Leu Glu Gly Arg Phe Trp Cys  
 85 90 95  
 Phe Leu Ser Glu Glu Asn Tyr Leu Phe Ile His Leu Asp Lys Gly Lys  
 100 105 110  
 Ile Arg Thr Ser Leu Val Glu His Cys Lys Gly Pro Lys Lys Lys Thr  
 115 120 125  
 Ala

<210> 3  
 <211> 298  
 <212> DNA  
 <213> Taenia solium

<220>  
 <221> CDS  
 <222> (3)..(224)

<400> 3  
 ta ttc gta gtg gcg gtt tcg gcc gag aaa aac aaa ccg aag tgt gat 47  
 Phe Val Val Ala Val Ser Ala Glu Lys Asn Lys Pro Lys Cys Asp  
 1 5 10 15  
 gca aat agt act aag aaa gag ata gaa tat atc cac aat tgg ttt ttc 95  
 Ala Asn Ser Thr Lys Lys Glu Ile Glu Tyr Ile His Asn Trp Phe Phe  
 20 25 30  
 cat gat gac ccg att gga aaa caa att gct caa ctc gca aag gac tgg 143

4

His Asp Asp Pro Ile Gly Lys Gln Ile Ala Gln Leu Ala Lys Asp Trp  
                   35                  40                  45

aat gaa aca gtg cag gaa gcc aaa ggc aaa ttt tgg gcg tca ctg gct 191  
 Asn Glu Thr Val Gln Glu Ala Lys Gly Lys Phe Trp Ala Ser Leu Ala  
           50                  55                  60

gag tac tgc aga ggt ctg aag aac aaa act gct taacttgatca actttcatgc 244  
 Glu Tyr Cys Arg Gly Leu Lys Asn Lys Thr Ala  
       65                  70

gttcttctct tcaccaataa atgctgatta acaagaaaaa aaaaaaaaaa aaaa 298

<210> 4  
 <211> 74  
 <212> PRT  
 <213> Taenia solium

<400> 4  
 Phe Val Val Ala Val Ser Ala Glu Lys Asn Lys Pro Lys Cys Asp Ala  
   1                  5                  10                  15

Asn Ser Thr Lys Lys Glu Ile Glu Tyr Ile His Asn Trp Phe Phe His  
           20                  25                  30

Asp Asp Pro Ile Gly Lys Gln Ile Ala Gln Leu Ala Lys Asp Trp Asn  
           35                  40                  45

Glu Thr Val Gln Glu Ala Lys Gly Lys Phe Trp Ala Ser Leu Ala Glu  
       50                  55                  60

Tyr Cys Arg Gly Leu Lys Asn Lys Thr Ala  
       65                  70

<210> 5  
 <211> 294  
 <212> DNA  
 <213> Taenia solium

<220>  
 <221> CDS  
 <222> (3)..(224)

<400> 5  
 tt ttc gta gtg gcg gtg tcg gcc gag gaa act aaa cca gag gac gtg 47  
   Phe Val Val Ala Val Ser Ala Glu Glu Thr Lys Pro Glu Asp Val  
     1                  5                  10                  15

gta aag aat att aag aaa ggg atg gaa gtt gtc tac aaa ttt ttc tac 95  
 Val Lys Asn Ile Lys Lys Gly Met Glu Val Val Tyr Lys Phe Phe Tyr  
           20                  25                  30

gaa gac ccg ttg gga aag aaa ata gct caa ctc gca aag gac tgg aag 143  
 Glu Asp Pro Leu Gly Lys Lys Ile Ala Gln Leu Ala Lys Asp Trp Lys  
           35                  40                  45

gaa gca atg ttg gaa gcc aga agc aaa gtg cgg gcg tca ctg gct gag 191

5

Glu Ala Met Leu Glu Ala Arg Ser Lys Val Arg Ala Ser Leu Ala Glu  
50 55 60

tac atc aga ggt ctc aag aac gaa gct gct taa cttgtcaact ttcattgcgtt 244  
 Tyr Ile Arg Gly Leu Lys Asn Glu Ala Ala  
 65 70

cttctcttca ctaataaatg ctcattaata agaaaaaaaaa aaaaaaaaaa 294

```
<210> 6
<211> 73
<212> PRT
<213> Taenia solium
```

<400> 6  
Phe Val Val Ala Val Ser Ala Glu Glu Thr Lys Pro Glu Asp Val Val  
1 5 10 15

Lys Asn Ile Lys Lys Gly Met Glu Val Val Tyr Lys Phe Phe Tyr Glu  
20 25 30

Asp Pro Leu Gly Lys Lys Ile Ala Gln Leu Ala Lys Asp Trp Lys Glu  
35 40 45

Ala Met Leu Glu Ala Arg Ser Lys Val Arg Ala Ser Leu Ala Glu Tyr  
50 55 60

Ile Arg Gly Leu Lys Asn Glu Ala Ala  
65 70

```
<210> 7
<211> 6
<212> PRT
<213> Taenia solium
```

```
<400> 7
Ile Ala Gln Leu Ala Lys
  1                      5
```

35

40

45

Ala Met Leu Glu Ala Arg Ser Lys Val Arg Ala Ser Leu Ala Glu Tyr  
50 55 60

Ile Arg Gly Leu Lys Asn Glu Ala Ala  
65 70

<210> 7  
<211> 6  
<212> PRT  
<213> Taenia solium

<400> 7

Ile Ala Gln Leu Ala Lys  
1 5

<210> 8  
<211> 24  
<212> PRT  
<213> Taenia solium

<220>  
<221> VARIANT  
<222> (7)..(8)  
<223> Amino acid at position 7 may also be valine

<220>  
<221> SITE  
<222> (21)..(22)  
<223> Asparagine at position 21 is an amino acid insertion

<220>  
<221> VARIANT  
<222> (14)..(15)  
<223> Amino acid at position 14 may also be glycine

<220>  
<221> VARIANT  
<222> (18)..(19)  
<223> Amino acid at position 18 may also be valine

<220>  
<221> VARIANT  
<222> (19)..(20)  
<223> Amino acid at position 19 may also be histidine

7

<220>  
<221> VARIANT  
<222> (20)..(21)  
<223> Amino acid at position 19 may also be arginine

<400> 8

Lys Asn Lys Pro Lys Asp Asp Ala Ala Ser Thr Lys Lys Glu Ile Glu  
1 5 10 15

Tyr Ile Trp His Asn Phe Phe Phe  
20

<210> 9  
<211> 13  
<212> PRT  
<213> Taenia solium

<220>  
<221> VARIANT  
<222> (5)..(6)  
<223> Amino acid at position 5 may also be isoleucine

<220>  
<221> VARIANT  
<222> (12)..(13)  
<223> Amino acid at position 12 may also be aspartic acid

<220>  
<221> VARIANT  
<222> (7)..(8)  
<223> Amino acid at position 7 may also be asparagine

<220>  
<221> SITE  
<222> (8)..(9)  
<223> Tryptophan at position 8 is an amino acid insertion

<400> 9

Gly Ile Glu Tyr Val His Glu Trp Phe Phe His Glu Asp  
1 5 10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number  
**WO 01/10897 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/12, C07K 14/435, G01N 33/53
- (21) International Application Number: PCT/US00/21173
- (22) International Filing Date: 3 August 2000 (03.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/147,318 5 August 1999 (05.08.1999) US
- (71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA** as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Centers for Disease Control and Prevention, Technology Transfer Office, Executive Park Drive, Building 4, Suite 1103, M/S E-67, Atlanta, GA 30329 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **TSANG, Victor, C., W.** [US/US]; 2595 Oak Crossing Drive, Decatur, GA 30033 (US). **GREENE, Ryan, M.** [US/US]; 1 Sycamore Station, Decatur, GA 30030 (US). **WILKINS, Patricia, P.** [US/US]; 5608 Hidden Harbor Drive, Gainesville, GA 30504 (US). **HANCOCK, Kathy** [US/US]; 1488 N. Amanda Circle, Atlanta, GA 30329 (US).
- (74) Agent: **NOONAN, William, D.**; Klarquist Sparkman Campbell Leigh & Winston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204-2988 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— With international search report.
- (88) Date of publication of the international search report:  
3 May 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS AND COMPOSITIONS FOR DETECTING LARVAL *TAENIA SOLIUM*

(57) Abstract: Compositions and methods for the detection of *Taenia solium* and the diagnosis and treatment of *T. solium* infection are described. The nucleotide and amino acid sequences of the antigenic polypeptides TS-14, TS-18 and TSRS-1 are provided. The compositions contain antigenic polypeptides of larval origin. The polypeptides are useful as research tools for studying *T. solium* and as reagents in assays for the detection of *T. solium* antibodies in a biological sample. The methods are sensitive and specific assays that utilize the antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.

WO 01/10897 A3

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 00/21173

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/435 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBL, BIOSIS, CHEM ABS Data, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RYAN M. GREENE ET AL.: "Diagnostic glycoproteins of Taenia solium cysts share homologous 14- and 18kDa subunits" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 99, no. 2, 30 April 1999 (1999-04-30), pages 257-261, XP000979008 page 258, right-hand column, paragraph 3 -page 260, left-hand column, paragraph 3 & DATABASE EMBL 'Online! Entry AF082830, 1 September 1999 (1999-09-01) GREENE R.M. ET AL.: "Taenia solium RS1 mRNA" & DATABASE EMBL 'Online! Entry AF082828, 1 September 1999 (1999-09-01) GREENE R.M. ET AL.: "Taenia solium 18kDa glycoprotein TS18 precursor" -/--	1-16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

23 January 2001

Date of mailing of the international search report

06/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

# INTERNATIONAL SEARCH REPORT

Inter. Application No.

PCT/US 00/21173

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p style="text-align: center;">---</p> <p>US 5 354 660 A (VICTOR C.W. TSANG ET AL.)  11 October 1994 (1994-10-11)  cited in the application  column 2, line 4 - line 39  column 3, line 4 - line 37; examples 1-3</p>	1,2,8,9, 13
X	<p style="text-align: center;">---</p> <p>CHARLES G.P. GAUCI ET AL.: "A Taenia solium oncosphere protein homologous to host-protective Taenia ovis and Taenia saginata 18 kDa antigens"  INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 28, May 1998 (1998-05), pages 757-760, XP000978965  page 757, right-hand column, paragraph 2  -page 759, right-hand column, paragraph 1; figures 1,2</p>	1,2,8,9, 13
X	<p style="text-align: center;">---</p> <p>HUBERT K ET AL: "SEROLOGICAL DIAGNOSIS OF HUMAN CYSTICERCOSIS BY USE OF RECOMBINANT ANTIGENS FROM TAENIA SOLIUM CYSTICERCI"  CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 6, no. 4, July 1999 (1999-07), pages 479-482, XP000965375  ISSN: 1071-412X  abstract  page 479, right-hand column, last paragraph -page 480, left-hand column, paragraph 3  page 480, left-hand column, last paragraph -page 481, right-hand column, paragraph 2</p>	1,8,13
X	<p style="text-align: center;">---</p> <p>US 4 801 532 A (RAYMOND E. KUHN ET AL.)  31 January 1989 (1989-01-31)  column 4, line 8 -column 7, line 33;  examples</p>	1,8,13
X	<p style="text-align: center;">---</p> <p>C. SIMAC ET AL.: "Use of enzyme-linked immunosorbent assay and enzyme-linked immunoelectrotransfer blot for the diagnosis and monitoring of neurocysticercosis"  PARASITOLOGY RESEARCH, vol. 81, 1995, pages 132-136, XP000978991  page 133, right-hand column, paragraph 4  -page 135, right-hand column, paragraph 2</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,2,8,9, 13

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/21173

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>GREENE RM ET AL.: "Molecular cloning and serological evaluation of taenia solium diagnostic"</p> <p>AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE,</p> <p>vol. 61, September 1999 (1999-09), page 178 XP000978963</p> <p>abstract no. 65</p> <p>---</p>	1-16
P,X	<p>DATABASE EMBL 'Online!</p> <p>Entry AF257776, 3 May 2000 (2000-05-03)</p> <p>TEALE J.M. ET AL.: "Taenia solium 14kDa glycoprotein mRNA"</p> <p>Database accession no. AF257776</p> <p>XP002158230</p> <p>the whole document</p> <p>-----</p>	1-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter Application No

PCT/US 00/21173

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5354660	A	11-10-1994	NONE	
US 4801532	A	31-01-1989	US 4740456 A	26-04-1988
			US 4855408 A	08-08-1989